OliX Pharmaceuticals lands ₩110.8B from L'Oréal's BOLD VC and Brookdale funds

What's the deal? South Korean biotech OliX (226950) is raising approximately ₩110.8B (roughly $80M) through a third-party share allocation. The round brings in L'Oréal's corporate venture fund BOLD (Business Opportunities for L'Oréal Development) and US asset manager Wise Asset Management's Brookdale funds — Brookdale Global Opportunity Fund and Brookdale International Partners.

The company will issue 740,367 new common shares at ₩149,599 per share. Proceeds will fund research and development and general operations.

Why now? OliX, which specialises in RNA interference therapeutics, is positioning itself for mid- to long-term growth. The investors were selected as strategic partners aligned with that trajectory, with long-term collaboration and information-sharing baked into the arrangement.

The new shares are set to list on July 17 and carry a mandatory one-year lock-up — a signal that both sides are in it for the long haul.

What could go wrong? A ₩110B capital raise through third-party allocation dilutes existing shareholders significantly. Biotech R&D timelines are notoriously unpredictable, and there's no guarantee the funds will translate into clinical or commercial milestones on schedule.

The signal: BOLD's backing of an early-growth RNA therapeutics firm highlights how corporate venture arms from the beauty and consumer goods sector are increasingly hunting for platform technologies at the intersection of biotech and dermatology. The mix of a European corporate VC and US institutional funds in a single Korean biotech round points to widening cross-border investor confidence in Asia's drug-development ecosystem.

Read more: edaily.co.kr